Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 16/20 | 0.48 |
| ▸ | PIK3R1 | P27986 | 4/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL735131 | 0.81 | PIK3CD (0.57) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL733665 | 0.79 | PIK3CD (0.51) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL15752919 | 0.78 | PIK3CD (0.48) | PIK3CDPIK3R1PIK3CGPIK3CBALDH1A1 | |
| SCHEMBL13161373 | 0.77 | PIK3CD (0.60) | PIK3CDPIK3R1PIK3CGPIK3CBALDH1A1 | |
| SCHEMBL734674 | 0.75 | PIK3CD (0.49) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL734000 | 0.75 | PIK3CD (0.45) | PIK3CDPIK3R1PIK3CGPIK3CBALDH1A1 | |
| SCHEMBL7174832 | 0.75 | PIK3CD (0.45) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL754017 | 0.75 | PIK3CD (0.64) | PIK3CDPIK3R1PIK3CGPIK3CBALDH1A1 | |
| SCHEMBL20717712 | 0.75 | PIK3CD (0.64) | PIK3CDPIK3R1PIK3CGPIK3CBALDH1A1 | |
| SCHEMBL3525027 | 0.75 | PIK3CD (0.59) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140154772-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2014-06-05 | — | — | US | claimed |
| US-20120135994-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2012-05-31 | — | — | US | claimed |
| EP-1278748-B1 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORP (US) | 2011-03-23 | — | — | EP | claimed |
| EP-1750715-A1 | METHODS FOR TREATING MAST CELL DISORDERS | ICOS CORPORATION (US) | 2007-02-14 | — | — | EP | claimed |
| US-20060106038-A1 | Methods for treating and/or preventing aberrant proliferation of hematopoietic cells | ICOS CORPORATION (US) | 2006-05-18 | — | — | US | claimed |
| US-20060079538-A1 | Methods for inhibiting angiogenesis | VANDERBILT UNIVERSITY | 2006-04-13 | — | — | US | claimed |
| WO-2005120511-A1 | METHODS FOR TREATING MAST CELL DISORDERS | ICOS CORPORATION (US) | 2005-12-22 | — | — | WO | claimed |
| US-20050261317-A1 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2005-11-24 | — | — | US | claimed |
| US-20050239809-A1 | Methods for treating and preventing hypertension and hypertension-related disorders | MICHIGAN STATE UNIVERSITY | 2005-10-27 | — | — | US | claimed |
| US-6949535-B2 | for example, 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-6,7-dimethoxy-3H-quinazolin-4-one | ICOS CORPORATION (US) | 2005-09-27 | — | — | US | claimed |
| US-20050054614-A1 | Methods of inhibiting leukocyte accumulation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-03-10 | — | — | US | claimed |
| US-20050043239-A1 | Methods of inhibiting immune responses stimulated by an endogenous factor | ICOS CORPORATION | 2005-02-24 | — | — | US | claimed |
| WO-2005016349-A1 | METHODS OF INHIBITING LEUKOCYTE ACCUMULATION | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | claimed |
| US-20040266780-A1 | for example, 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-6,7-dimethoxy-3H-quinazolin-4-one | ICOS CORPORATION | 2004-12-30 | — | — | US | claimed |
| US-20030195211-A1 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION | 2003-10-16 | — | — | US | claimed |
| US-6518277-B1 | Disrupting leukocyte function | ICOS CORPORATION | 2003-02-11 | — | — | US | claimed |
| US-20020161014-A1 | Purinyl substituted quinazoline-4-one derivatives | ICOS CORPORATION, A DELAWARE CORPORATION | 2002-10-31 | — | — | US | claimed |
| US-10695349-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
| US-6518277-B1 | Disrupting leukocyte function | ICOS CORPORATION | 2003-02-11 | — | — | US | disclosed |
| US-20020161014-A1 | Purinyl substituted quinazoline-4-one derivatives | ICOS CORPORATION, A DELAWARE CORPORATION | 2002-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054614-A1 | Methods of inhibiting leukocyte accumulation | PI4KB, PIK3CD, PIK3CA | PIK3CD 2/4885PIK3R1 14/4885PIK3CG 7/4885 |
| US-20140154772-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | PIK3CD 1/4885PIK3R1 12/4885PIK3CG 3/4885 |
| US-20120135994-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | PIK3CD 1/4885PIK3R1 12/4885PIK3CG 3/4885 |
| US-20020161014-A1 | Purinyl substituted quinazoline-4-one derivatives | PIK3CD, PIK3CA, PIK3CG | PIK3CD 1/4885PIK3R1 18/4885PIK3CG 3/4885 |
| US-20060079538-A1 | Methods for inhibiting angiogenesis | FLT4, KDR, PDGFRB | PIK3CD 6/4885PIK3R1 22/4885PIK3CG 13/4885 |
| US-20050261317-A1 | Inhibitors of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3R5, PIK3CA | PIK3CD 1/4885PIK3R1 20/4885PIK3CG 4/4885 |
| US-20040266780-A1 | for example, 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-6,7-dimethoxy-3H-quinazolin-4-one | PIK3CD, PIK3CA, PIK3CG | PIK3CD 1/4885PIK3R1 7/4885PIK3CG 3/4885 |
| US-20050239809-A1 | Methods for treating and preventing hypertension and hypertension-related disorders | PRKCH, PTEN, PRKCA | PIK3CD 4/4885PIK3R1 82/4885PIK3CG 6/4885 |
| US-20050043239-A1 | Methods of inhibiting immune responses stimulated by an endogenous factor | PI4KB, PI4KA, PIK3CD | PIK3CD 3/4885PIK3R1 46/4885PIK3CG 10/4885 |
| US-20060106038-A1 | Methods for treating and/or preventing aberrant proliferation of hematopoietic cells | MCL1, NFATC1, MKI67 | PIK3CD 25/4885PIK3R1 84/4885PIK3CG 57/4885 |
| US-20030195211-A1 | Inhibitors of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3CA, PIK3CG | PIK3CD 1/4885PIK3R1 12/4885PIK3CG 3/4885 |
| US-10695349-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3CA, PIK3CG | PIK3CD 1/4885PIK3R1 12/4885PIK3CG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.